As 1 paradigm-defining example of precision medicine, activating mutations in the EGFR are associated with high response rates to EGFR-directed tyrosine kinase inhibitors (TKIs) in non–small cell lung cancer (NSCLC) (1). Here, EGFR is linked to lung cancer.